- Collaborative efforts are aimed at using Lantern’s AI platform
to accelerate and sharpen the drug development of TTC-352.
- The collaboration will utilize Lantern’s AI-based capabilities
and RADR® platform to uncover efficacy-associated biological
signatures and biomarkers to advance the clinical development and
strategic positioning of TTC Oncology’s leading drug candidate,
TTC-352.
- Phase 2 ready candidate, TTC-352, is a novel, first- and
best-in-class selective human estrogen receptor (ER) partial
agonist (ShERPA) for the treatment of patients with metastatic ER+
breast cancer.
- Lantern is receiving exclusive rights to license TTC-352 during
an exclusive option period, which includes rights to intellectual
property generated during the collaboration.
Lantern Pharma Inc. (NASDAQ: LTRN), a clinical stage
biopharmaceutical company using its proprietary RADR® artificial
intelligence ("AI") and machine learning (“ML”) platform to
transform the cost, pace, and timeline of oncology drug discovery
and development, today announced that it has entered into a
research and development collaboration with TTC Oncology. The
collaboration will focus on leveraging RADR® AI insights to advance
TTC Oncology’s first- and best-in-class drug candidate TTC-352 for
recurrent ER+ breast cancer patients and additional patient
populations potentially identified by RADR®. In US women, breast
cancer remains the most commonly diagnosed cancer and second
leading cause of cancer related deaths. ER+ breast cancers are
estimated to account for 75-80% of all breast cancer cases and can
have a recurrence rate between 13% and 41%. Globally, the treatment
of ER+ breast cancer is estimated to have a $44 billion market
potential by 2027.
”It is of the utmost importance for cancer drug development to
understand targeted tumor biology and mechanisms of resistance in
order to select the patient population that will benefit the most
from novel therapy. We expect that by using Lantern’s RADR® AI
platform it can save us time and costs in the further successful
clinical development of TTC-352 while providing important
information for precision patient selection,” said Dr. Arkadiusz
Dudek, TTC Oncology Chief Medical Officer.
The collaboration will be powered by RADR®’s 25+ billion
oncology-focused data points, 200+ advanced ML algorithms, as well
as its 4 multi-faceted AI drug discovery and development modules.
The initial aims of the collaboration will be to 1) identify
biomarker or gene signatures to power potential patient selection
for an upcoming TTC-352 Phase 2 clinical trial, 2) further
characterize TTC-352’s mechanism of action, and 3) discover
additional treatment indications for TTC-352.
“Using AI insights generated by RADR®, we are able to both
sharpen existing clinical programs and uncover additional
unrealized clinical potential of Lantern’s and our collaborators’
drug candidates,” stated Panna Sharma, Lantern Pharma’s CEO and
President. “We believe our AI-powered collaboration with TTC
Oncology will accelerate the clinical development of TTC-352 for
patients with metastatic ER+ breast cancer and will also identify
new potential patient populations that can benefit from TTC-352
treatment,” continued Sharma.
Under the terms of the collaboration, Lantern Pharma is
receiving an exclusive right to license TTC-352, including any
collaboration intellectual property (IP), during an exclusive
option period. Additionally, Lantern and TTC will each participate
in upfront, milestone, and royalty payments in the event a third
party licenses IP resulting from the collaboration. No further
financial details were disclosed.
About RADR®
RADR® is one of the world’s largest AI and ML oncology drug
discovery and development platforms, consisting of over 25+ billion
oncology-focused data points. These data points consist of
large-scale multi-omic data, derived from 130,000+ patient records,
150+ drug-tumor interactions, thousands of drug classes, and
covering over 135 cancer subtypes. RADR® leverages this data and
over 200+ advanced ML algorithms to power its drug discovery and
development modules. RADR®’s data, capabilities, and insights have
powered the development of new Lantern drug candidates, advancement
of new indications for existing drugs, and identification of new
combinations at a fraction of the cost and time of traditional
development approaches.
About TTC-352
TTC-352 is a novel, first-in-class and best-in-class orally
available small molecule being developed as a treatment for
patients with metastatic estrogen receptor-positive (ER+) breast
cancer who have failed 2 or more prior therapies. TTC-352 is a
selective human ER partial agonist (ShERPA) that induces unfolded
protein response leading to breast cancer cell death, and acts in a
similar manner as hormone therapy by modulating estrogen actions.
In the US there are estimated to be around 290,000 cases of breast
cancer annually, 80% of which are ER+.
TTC-352 was recently evaluated in a Phase 1 accelerated dose
escalation study (NCT03201913) for hormone receptor positive
metastatic breast cancer. A total of fifteen patients (n=15) were
enrolled in the study and five escalating doses were evaluated.
Despite the small cohort size, TTC-352 showed early efficacy
signals in heavily pretreated hormone refractory patients (Median
PFS was 58 days (95% CI = 28,112)) and showed a favorable safety
profile. Additional published trial results can be found here.
About TTC Oncology
TTC Oncology is an emerging biotechnology company founded in
2015. TTC Oncology’s mission is to develop and bring to market a
novel, small-molecule therapy, TTC-352, to address the unmet needs
of breast cancer patients. TTC has a license from the University of
Illinois at Chicago covering the therapy.
About Lantern Pharma
Lantern Pharma (NASDAQ: LTRN) is a clinical-stage
oncology-focused biopharmaceutical company leveraging its
proprietary RADR® AI and machine learning platform to discover
biomarker signatures that identify patients most likely to respond
to its pipeline of genomically-targeted therapeutics. By targeting
drugs to patients whose genomic profile identifies them as having
the highest probability of benefiting from the drug, Lantern's
approach represents the potential to deliver best-in-class
outcomes.
Forward-looking Statements
This press release contains forward-looking statements within
the meaning of Section 27A of the Securities Act of 1933, as
amended, and Section 21E of the Securities Exchange Act of 1934, as
amended. These forward-looking statements include, among other
things, statements relating to: future events or our future
financial performance; the potential advantages of our RADR®
platform in identifying drug candidates and patient populations
that are likely to respond to a drug candidate; our strategic plans
to advance the development of our drug candidates and antibody drug
conjugate (ADC) development program; estimates regarding the
development timing for our drug candidates and ADC development
program; expectations and estimates regarding clinical trial timing
and patient enrollment; our research and development efforts of our
internal drug discovery programs and the utilization of our RADR®
platform to streamline the drug development process; our intention
to leverage artificial intelligence, machine learning and genomic
data to streamline and transform the pace, risk and cost of
oncology drug discovery and development and to identify patient
populations that would likely respond to a drug candidate;
estimates regarding patient populations, potential markets and
potential market sizes; sales estimates for our drug candidates and
our plans to discover and develop drug candidates and to maximize
their commercial potential by advancing such drug candidates
ourselves or in collaboration with others. Any statements that are
not statements of historical fact (including, without limitation,
statements that use words such as "anticipate," "believe,"
"contemplate," "could," "estimate," "expect," "intend," "seek,"
"may," "might," "plan," "potential," "predict," "project,"
"target," "model," "objective," "aim," "upcoming," "should,"
"will," "would," or the negative of these words or other similar
expressions) should be considered forward-looking statements. There
are a number of important factors that could cause our actual
results to differ materially from those indicated by the
forward-looking statements, such as (i) the impact of the COVID-19
pandemic, (ii) the risk that our research and the research of our
collaborators may not be successful, (iii) the risk that none of
our product candidates has received FDA marketing approval, and we
may not be able to successfully initiate, conduct, or conclude
clinical testing for or obtain marketing approval for our product
candidates, (iv) the risk that no drug product based on our
proprietary RADR® AI platform has received FDA marketing approval
or otherwise been incorporated into a commercial product, and (v)
those other factors set forth in the Risk Factors section in our
Annual Report on Form 10-K for the year ended December 31, 2021,
filed with the Securities and Exchange Commission on March 10,
2022. You may access our Annual Report on Form 10-K for the year
ended December 31, 2021 under the investor SEC filings tab of our
website at www.lanternpharma.com or on the SEC's website at
www.sec.gov. Given these risks and uncertainties, we can give no
assurances that our forward-looking statements will prove to be
accurate, or that any other results or events projected or
contemplated by our forward-looking statements will in fact occur,
and we caution investors not to place undue reliance on these
statements. All forward-looking statements in this press release
represent our judgment as of the date hereof, and, except as
otherwise required by law, we disclaim any obligation to update any
forward-looking statements to conform the statement to actual
results or changes in our expectations.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230227005262/en/
Nicole Leber Investor Relations Associate
ir@lanternpharma.com
Please find more information at: Website: www.lanternpharma.com
LinkedIn: https://www.linkedin.com/company/lanternpharma/ Twitter:
@lanternpharma Lantern’s Monthly Newsletter – SPARK: Sign-up
here
Lantern Pharma (NASDAQ:LTRN)
Historical Stock Chart
From Jun 2024 to Jul 2024
Lantern Pharma (NASDAQ:LTRN)
Historical Stock Chart
From Jul 2023 to Jul 2024